HRH3 and Ehlers-Danlos syndrome: Among these drug options, modafinil (norepinephrine and dopamine reuptake blocker), solriamfetol (selective dopamine and norepinephrine reuptake inhibitor), and pitolisant (selective histamine H3-receptor antagonist) may be used for the treatment of residual EDS complaints in treated apneic individuals given their wake-promoting properties [57,58].